drugset / Trial / NCT05813717

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

NCT05813717 ↗

Phase 1 Completed 25 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986325 in healthy Japanese participants

Timeline

Start
2023-04-10
Primary completion
2023-10-02
Completion
2023-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986325 Unknown — —

Indications

No indication recorded.